Loading company…
Radionetics Oncology develops targeted radiopharmaceuticals for solid tumors.
Radionetics Oncology is developing small molecule radiopharmaceuticals that target cancer cells, including therapies aimed at G protein-coupled receptors. Founded in 2021, the company is based in Menlo Park, US. It raised USD 54.21 mn in Series A funding as of August 1, 2023, from GordonMD Global Investments and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in